NurExone Biologic Inc.
A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment
Published: 12/16/2024
Author: FRC Analysts

Sector: Healthcare | Industry: Biotechnology
Ticker Symbols:NRX.V - TSX 🔹
Rating and Key Data
Metrics | Value |
---|---|
Current Price | CAD $0.77 |
Fair Value | CAD $2 |
Risk | 5 |
52 Week Range | CAD $0.26-1.19 |
Shares O/S (M) | 71 |
Market Cap. (M) | CAD $55 |
Current Yield (%) | N/A |
P/E (forward) | N/A |
P/B | N/A |
Already a subscriber?
Want to know the fair value of the stock?
Subscribe for free to get exclusive insights and data.
Report Highlights
- NRX, an Israeli biotech company founded in 2020, is developing a novel drug delivery platform designed to provide minimally invasive, highly targeted solutions to address unmet medical needs.
- The company leverages exosomes, tiny, naturally occurring cellular sacs, to deliver medication directly to inflamed or damaged tissues. This targeted approach offers potential advantages over traditional gene and cell therapies. While the exosome therapeutics industry is emerging, there are currently no FDA-approved products.
- NRX is focused on treating central nervous system injuries, spinal cord injury (SCI), optic nerve injury, brain trauma, and neurological conditions through regenerative medicine. Its lead pro